Difference between revisions of "Myeloproliferative neoplasms"
Jump to navigation
Jump to search
m (→References) |
m (→Grouping: fix spell.) |
||
| Line 3: | Line 3: | ||
==Grouping== | ==Grouping== | ||
They include the following:<ref name=pmid15781101>{{cite journal |author=Baxter EJ, Scott LM, Campbell PJ, ''et al.'' |title=Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders |journal=Lancet |volume=365 |issue=9464 |pages=1054–61 |year=2005 |pmid=15781101 |doi=10.1016/S0140-6736(05)71142-9 |url=}}</ref> | They include the following:<ref name=pmid15781101>{{cite journal |author=Baxter EJ, Scott LM, Campbell PJ, ''et al.'' |title=Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders |journal=Lancet |volume=365 |issue=9464 |pages=1054–61 |year=2005 |pmid=15781101 |doi=10.1016/S0140-6736(05)71142-9 |url=}}</ref> | ||
* | *Polycythemia vera. | ||
*Essential thrombocythaemia. | *Essential thrombocythaemia. | ||
*Idiopathic myelofibrosis. | *Idiopathic myelofibrosis. | ||
Revision as of 14:10, 4 May 2011
Myeloproliferative neoplasms, also myeloproliferative disorders, are a group of indolent hematologic neoplasms.
Grouping
They include the following:[1]
- Polycythemia vera.
- Essential thrombocythaemia.
- Idiopathic myelofibrosis.
Molecular
A specific JAK2 mutation (Val617Phe) in seen in a group of patients.[1][2]
See also
References
- ↑ 1.0 1.1 Baxter EJ, Scott LM, Campbell PJ, et al. (2005). "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders". Lancet 365 (9464): 1054–61. doi:10.1016/S0140-6736(05)71142-9. PMID 15781101.
- ↑ Steensma DP, Dewald GW, Lasho TL, et al. (August 2005). "The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes". Blood 106 (4): 1207–9. doi:10.1182/blood-2005-03-1183. PMC 1895198. PMID 15860661. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895198/.